FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> NicVAX | Nabi Biopharmaceuticals

Nabi lands $10M for anti-smoking vaccine

Tools

The National Institute on Drug Abuse has given Nabi Biopharmaceuticals a $10 million loan to help fund the company's first pivotal clinical trial of NicVAX, a smoking cessation vaccine. It's the largest grant the NIDA has ever handed out, and the third Nabi has received. The company was granted funding during NicVAX's preclinical development and and additional $4.1 million for Phase II testing. And the FDA has given the vaccine fast-track status.

"We are very pleased to be awarded this generous grant from NIDA which enables us to proceed with the first pivotal Phase III trial for NicVAX," said Dr. Raafat Fahim, Nabi Biopharmaceuticals' CEO. "...This grant will defray a significant portion of the expense of the first phase III study." Nabi will continue to pursue partnering discussions for the future development and commercialization of the vaccine.

- here's the Nabi release
- see the report

Related Articles:
Nabi sells staph vax program to GSK for $46M
Nabi CEO walks after hedge fund balks
Nabi, FDA agree on SPA for NicVAx
Positive Phase II results for anti-smoking vaccine

More stories about Nabi Biopharmaceuticals   NicVAX  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.